China, Pharmaceutical | JD Supra Law News

China Life Sciences Health Industry Client Briefing – April 2013 (May 15, 2013)

by Vicki Lung, Gordon B. Schatz, Katherine Yang, Amy Yin | Reed Smith on 5/15/2013

Pharmaceuticals, Medical Devices, Health Care & Life Sciences - ..Drugs - Approval of Innovative Drugs and Key Sector Generic Drugs to be Expedited (Shanghai Securities Journal 2013-04-23): Given the...more

China Life Sciences Health Industry Client Briefing – March 2013 (April 26, 2013)

by Vicki Lung, Gordon B. Schatz, Katherine Yang, Amy Yin | Reed Smith on 4/29/2013

Pharmaceuticals, Medical Devices, Health Care & Life Sciences - ..Medical Devices - CFDA Seeks Public Comment on Special Approval Procedures for Innovative Medical Devices: China Food and Drug...more

China Releases New Essential Drug List

by Katherine Wang | Ropes & Gray LLP on 3/22/2013

China’s Ministry of Health released the new essential drug list (the “2012 EDL”) on March 15, 2013, effective as of May 1, 2013. Essential drugs are those which meet basic health care demands in suitable dosage forms with...more

China Clarifies Fast Track Approval Eligibility for Novel Biologics

by Katherine Wang | Ropes & Gray LLP on 3/13/2013

The Chinese State Food and Drug Administration (“SFDA”) created a fast track review and approval process for novel drugs in its Drug Registration Rules issued in 2007. The fast track approval process is available for (1)...more

China Life Sciences Health Industry Client Briefing – February 2013 (March 11, 2013)

by Vicki Lung, Mao Rong, Gordon B. Schatz, John Tan, May Ling Wong, Jay J. Yan, Katherine Yang, Amy Yin | Reed Smith on 3/12/2013

In This Issue: New Drug GSP Issued: Supervision on Drug Distribution to be Enhanced (China Securities Journal 2013-02-20) – February 20, 2013; China to Encourage Innovative Drug Development (Xinhua News Agency...more

China SFDA Creates New Regulatory Pathways for Transfer of Drug Licenses

by Katherine Wang | Ropes & Gray LLP on 3/4/2013

To accelerate GMP compliance by domestic pharmaceutical companies, the Chinese State Food and Drug Administration (“SFDA”) published a notice on February 22, 2013 (the “Notice”) clarifying the regulatory pathways for...more

China Life Sciences Health Industry Client Briefing – January 2013 (February 21, 2013)

by Vicki Lung, Mao Rong, Gordon B. Schatz, John Tan, May Ling Wong, Jay J. Yan, Katherine Yang, Amy Yin | Reed Smith on 2/22/2013

In This Issue: Li Keqiang Comments from the 12th Plenary Meeting of the Medical Reform Leading Group (USCBC 2012-01-06) – January 6, 2013; MOH Announces Roadmap for Medical Reform (USCBC 2012-01-10) – January 10, 2013;...more

China Amended Good Supply Practices for Pharmaceuticals

by Katherine Wang | Ropes & Gray LLP on 2/21/2013

The Chinese Ministry of Health (“MOH”) published the long-awaited amendment of Good Supply Practices for Pharmaceuticals (the “Amended GSP”) on January 22, 2013, to be effective as of June 1, 2013. After three rounds of...more

China Life Sciences Health Industry Client Briefing - December 2012 (January 18, 2013)

by Vicki Lung, Mao Rong, Gordon B. Schatz, John Tan, May Ling Wong, Jay J. Yan, Katherine Yang | Reed Smith on 1/24/2013

Pharmaceuticals, Medical Devices, Health Care & Life Sciences - News & Regulations: ..Industry Calls for Reform of Lagging Drug Review System (Global Times 2012-12-02) – December 3, 2012...more

China Trade Marks – Inclusion of Retail and Wholesale services relating to medicines and pharmaceuticals

by Jonathan Feder, Shalini Jayaweera, Anthony Watson | K&L Gates LLP on 1/21/2013

The China Trade Marks Office (CTMO) recently announced that from 1 January 2013 it is accepting applications to register trade marks in relation to retail or wholesale services for pharmaceutical, veterinary and sanitary...more

Skadden's 2013 Insights: Global Litigation

by Skadden, Arps, Slate, Meagher & Flom LLP on 1/21/2013

New legal ground is expected to be broken this year in areas of importance to companies and their directors, officers and executives. We see those developments coming from around the globe and defining the litigation...more

Chinese MOH Announced Centralized Procurement of High Value Medical Consumables

by Katherine Wang | Ropes & Gray LLP on 1/18/2013

On December 17, 2012, the Ministry of Health (“MOH”) issued the Tentative Guidelines for Centralized Procurement of High Value Medical Consumables (the “Guidelines”) with immediate effect, with an aim to control health care...more

China Life Sciences - January 2013

by Gabriel Bloch, Peng Chen, Gordon Milner, Kun Wang | Morrison & Foerster LLP on 1/17/2013

In This Issue: Investor Q&A; Key Regulatory Issues for Strategic Life Sciences Partnerships in China; Compulsory Patent Licensing in China; and New Developments on the “Patentable Subject Matter” Requirement of U.S....more

China Life Sciences and Health Industry Client Briefing – November 2012 (December 13, 2012)

by Mao Rong, Gordon B. Schatz, Hugh T. Scogin , Jr., John Tan, May Ling Wong, Jay J. Yan, Katherine Yang, Amy Yin | Reed Smith on 12/17/2012

In This Issue: Priorities, Practical Tips and Lessons Learned from Reed Smith’s China Device Regulatory Briefing on December 4, 2012; Programs of Designated Drug Production to be Initiated: Five to 10 Pilot Varieties...more

China Life Sciences: Moving Towards Full Impact

by Morrison & Foerster LLP on 8/16/2010

I recently spent some time in the “Golden Triangle,” which on its Northern edge is delineated by the area between Nanjing and Shanghai. What is initially striking is the absolutely mammoth investment in infrastructure that...more

Home

Legal News

Find a Lawyer

Browse Subjects

Subscribe

Pro Services

For Reporters

China › Pharmaceutical